$NWBO
NORTHWEST BIOTHERAPEUTICS INC

2021 Q2 Form 10-Q Financial Statement

#000110465921106389 Filed on August 16, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2 2020 Q1
Revenue $416.0K $2.000K $570.0K
YoY Change 20700.0% -99.66% 68.14%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.372M $4.318M $4.546M
YoY Change 70.73% 9.96% -10.88%
% of Gross Profit
Research & Development $5.451M $3.220M $3.857M
YoY Change 69.29% -2.16% 28.4%
% of Gross Profit
Depreciation & Amortization $77.00K $2.000K $14.00K
YoY Change 3750.0% -66.67% 600.0%
% of Gross Profit
Operating Expenses $5.451M $3.220M $3.857M
YoY Change 69.29% -2.16% 28.4%
Operating Profit -$12.41M -$7.536M -$7.833M
YoY Change 64.64% 13.55% 0.86%
Interest Expense $807.0K $1.059M $625.0K
YoY Change -23.8% 34.56% -17.33%
% of Operating Profit
Other Income/Expense, Net $16.82M -$50.52M $10.46M
YoY Change -133.29% -836.81% -179.36%
Pretax Income $4.410M -$58.05M $2.726M
YoY Change -107.6% -26607.76% -113.01%
Income Tax
% Of Pretax Income
Net Earnings $4.410M -$58.05M $2.626M
YoY Change -107.6% -26607.76% -112.54%
Net Earnings / Revenue 1060.1% -2902600.0% 460.7%
Basic Earnings Per Share $0.01 -$0.08 $0.00
Diluted Earnings Per Share -$0.01 -$0.08 $0.00
COMMON SHARES
Basic Shares Outstanding 851.8K 697.6K 640.4K
Diluted Shares Outstanding 1.159M 697.6K 648.9K

Balance Sheet

Concept 2021 Q2 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.758M $5.955M $764.0K
YoY Change -36.89% -10.8% -95.31%
Cash & Equivalents $3.758M $5.955M $764.0K
Short-Term Investments
Other Short-Term Assets $4.591M $2.262M $2.844M
YoY Change 102.96% 1.43% 24.03%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $8.349M $8.217M $3.608M
YoY Change 1.61% -7.74% -80.58%
LONG-TERM ASSETS
Property, Plant & Equipment $1.312M $157.0K $4.822M
YoY Change 735.67% -96.87% 1640.79%
Goodwill $626.0K
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.093M $755.0K $753.0K
YoY Change 44.77% -2.58% 0.67%
Total Long-Term Assets $20.42M $6.689M $5.575M
YoY Change 205.25% 15.37% -5.33%
TOTAL ASSETS
Total Short-Term Assets $8.349M $8.217M $3.608M
Total Long-Term Assets $20.42M $6.689M $5.575M
Total Assets $28.77M $14.91M $9.183M
YoY Change 92.99% 1.37% -62.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.35M $8.190M $7.996M
YoY Change 38.52% 27.27% -55.69%
Accrued Expenses $249.0K $311.0K $384.0K
YoY Change -19.94% 11.07% 42.22%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $7.655M $12.88M $12.32M
YoY Change -40.56% -12.32%
Total Short-Term Liabilities $360.7M $88.57M $39.66M
YoY Change 307.26% 59.69% -46.56%
LONG-TERM LIABILITIES
Long-Term Debt $12.40M $3.173M $0.00
YoY Change 290.64% -58.01% -100.0%
Other Long-Term Liabilities $5.506M $4.480M $4.516M
YoY Change 22.9% -4.48% -4.91%
Total Long-Term Liabilities $17.90M $7.653M $4.516M
YoY Change 133.91% -37.51% -48.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $360.7M $88.57M $39.66M
Total Long-Term Liabilities $17.90M $7.653M $4.516M
Total Liabilities $378.6M $96.22M $44.18M
YoY Change 293.47% 42.11% -46.76%
SHAREHOLDERS EQUITY
Retained Earnings -$1.371B -$895.1M
YoY Change 53.15%
Common Stock $1.022B $812.2M
YoY Change 25.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$349.8M -$83.01M -$36.58M
YoY Change
Total Liabilities & Shareholders Equity $28.77M $14.91M $9.183M
YoY Change 92.99% 1.37% -62.47%

Cashflow Statement

Concept 2021 Q2 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income $4.410M -$58.05M $2.626M
YoY Change -107.6% -26607.76% -112.54%
Depreciation, Depletion And Amortization $77.00K $2.000K $14.00K
YoY Change 3750.0% -66.67% 600.0%
Cash From Operating Activities -$6.792M -$6.329M -$7.539M
YoY Change 7.32% -34.6% -22.68%
INVESTING ACTIVITIES
Capital Expenditures -$1.507M -$1.244M -$62.00K
YoY Change 21.14% 1939.34% -62.2%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.507M -$1.244M -$62.00K
YoY Change 21.14% 1939.34% -62.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.781M 13.17M 7.025M
YoY Change -63.71% 45324.14% 78.34%
NET CHANGE
Cash From Operating Activities -6.792M -6.329M -7.539M
Cash From Investing Activities -1.507M -1.244M -62.00K
Cash From Financing Activities 4.781M 13.17M 7.025M
Net Change In Cash -3.518M 5.600M 392.0K
YoY Change -162.82% -157.67% -106.56%
FREE CASH FLOW
Cash From Operating Activities -$6.792M -$6.329M -$7.539M
Capital Expenditures -$1.507M -$1.244M -$62.00K
Free Cash Flow -$5.285M -$5.085M -$7.477M
YoY Change 3.93% -47.12% -22.01%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Goodwill
Goodwill
626000
CY2020Q4 us-gaap Goodwill
Goodwill
626000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1093000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
867000
CY2021Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
20418000
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
17388000
CY2021Q2 us-gaap Assets
Assets
28767000
CY2020Q4 us-gaap Assets
Assets
32899000
CY2021Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
8162000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7380000
CY2021Q2 nwbo Accounts Payable And Accrued Liabilities Related Parties Current
AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent
3183000
CY2020Q4 nwbo Accounts Payable And Accrued Liabilities Related Parties Current
AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent
5363000
CY2021Q2 nwbo Convertible Notes Payable Net Current
ConvertibleNotesPayableNetCurrent
135000
CY2020Q4 nwbo Convertible Notes Payable Net Current
ConvertibleNotesPayableNetCurrent
3830000
CY2021Q2 us-gaap Notes Payable Current
NotesPayableCurrent
7520000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
2437000
CY2021Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
8656000
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
8275000
CY2021Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
332803000
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
354972000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
249000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
167000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
360708000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
382424000
CY2021Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
12395000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8507000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5506000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4916000
CY2021Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
17901000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
13423000
CY2021Q2 us-gaap Liabilities
Liabilities
378609000
CY2020Q4 us-gaap Liabilities
Liabilities
395847000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1200000000
dei Entity Address City Or Town
EntityAddressCityOrTown
Bethesda
dei Entity Address Country
EntityAddressCountry
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20814
dei City Area Code
CityAreaCode
240
dei Local Phone Number
LocalPhoneNumber
497-9024
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
857200000
dei Security Exchange Name
SecurityExchangeName
NONE
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35737
dei Entity Registrant Name
EntityRegistrantName
NORTHWEST BIOTHERAPEUTICS, INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3306718
dei Entity Address Address Line1
EntityAddressAddressLine1
4800 Montgomery Lane, Suite 800
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Central Index Key
EntityCentralIndexKey
0001072379
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
829600000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
NWBO
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
872440436
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3758000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9983000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4591000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5528000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
8349000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
15511000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1312000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1040000
CY2021Q2 nwbo Constructions In Progress Net
ConstructionsInProgressNet
10988000
CY2020Q4 nwbo Constructions In Progress Net
ConstructionsInProgressNet
9074000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5107000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4489000
CY2021Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1292000
CY2020Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1292000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1200000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
857200000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
829600000
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
857000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
830000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1021107000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1008665000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1371216000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-798000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1148000
CY2021Q2 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
79000
CY2020Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
79000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1370929000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12407000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7536000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15369000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-349842000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-362948000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28767000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32899000
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
416000
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
655000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
572000
CY2021Q2 us-gaap Revenues
Revenues
416000
CY2020Q2 us-gaap Revenues
Revenues
2000
us-gaap Revenues
Revenues
655000
us-gaap Revenues
Revenues
572000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5451000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3220000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12374000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7077000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7372000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4318000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20258000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8864000
CY2021Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
12823000
CY2020Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
7538000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
32632000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
15941000
us-gaap Operating Income Loss
OperatingIncomeLoss
-31977000
CY2021Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
17500000
CY2020Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-49128000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
35063000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-36201000
CY2021Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-136000
CY2020Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-551000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-144000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1266000
CY2021Q2 us-gaap Interest Expense
InterestExpense
807000
CY2020Q2 us-gaap Interest Expense
InterestExpense
1059000
us-gaap Interest Expense
InterestExpense
2254000
us-gaap Interest Expense
InterestExpense
1684000
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
260000
CY2020Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
222000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-401000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-906000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16817000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-50516000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
32264000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-40057000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
4410000
nwbo Proceeds From Issuance Of Convertible Notes Payable
ProceedsFromIssuanceOfConvertibleNotesPayable
2189000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
315000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
835000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1363000
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
64000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15542000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20198000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
44000
nwbo Value Of Warrants And Stock Options Exercised For Cash
ValueOfWarrantsAndStockOptionsExercisedForCash
4073000
nwbo Adjustments To Additional Paid In Capital Reclassification
AdjustmentsToAdditionalPaidInCapitalReclassification
11394000
nwbo Adjustment To Additional Paid In Capital Reclassification Of Cashless Warrants Exercised
AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised
1592000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13442000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-58052000
us-gaap Net Income Loss
NetIncomeLoss
287000
us-gaap Net Income Loss
NetIncomeLoss
-55426000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
274000
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
278000
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-350000
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-763000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4136000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-58330000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
637000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54663000
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
851805
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
697555
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
843252
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
668972
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1159076
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
697555
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1147423
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
668972
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-353200000
CY2021Q2 nwbo Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest
StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest
881000
CY2021Q2 nwbo Value Of Warrants And Stock Options Exercised For Cash
ValueOfWarrantsAndStockOptionsExercisedForCash
3328000
CY2021Q2 nwbo Adjustments To Additional Paid In Capital Reclassification
AdjustmentsToAdditionalPaidInCapitalReclassification
8459000
CY2021Q2 nwbo Adjustment To Additional Paid In Capital Reclassification Of Cashless Warrants Exercised
AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised
1446000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3551000
CY2021Q2 nwbo Adjustment To Additonal Paid In Capital Reclassification Of Warrant Liabilities Based On Authorized Shares
AdjustmentToAdditonalPaidInCapitalReclassificationOfWarrantLiabilitiesBasedOnAuthorizedShares
18443000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
4410000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-274000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-349842000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-36580000
CY2020Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
2903000
CY2020Q2 nwbo Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest
StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest
2249000
CY2020Q2 nwbo Value Of Warrants Exercised For Cash
ValueOfWarrantsExercisedForCash
3997000
CY2020Q2 nwbo Adjustments To Additional Paid In Capital Reclassification
AdjustmentsToAdditionalPaidInCapitalReclassification
2721000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
35000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-58052000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-278000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-83005000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-362948000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16000
nwbo Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest
StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest
7500000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-36201000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-144000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1266000
nwbo Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
149000
nwbo Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
163000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
13369000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
399000
nwbo Adjustment To Additonal Paid In Capital Reclassification Of Warrant Liabilities Based On Authorized Shares
AdjustmentToAdditonalPaidInCapitalReclassificationOfWarrantLiabilitiesBasedOnAuthorizedShares
25548000
us-gaap Net Income Loss
NetIncomeLoss
287000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
350000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-349842000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-45055000
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
4948000
nwbo Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest
StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest
4648000
nwbo Value Of Warrants Exercised For Cash
ValueOfWarrantsExercisedForCash
3997000
nwbo Adjustments To Additional Paid In Capital Reclassification
AdjustmentsToAdditionalPaidInCapitalReclassification
2721000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
399000
us-gaap Net Income Loss
NetIncomeLoss
-55426000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
763000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-83005000
us-gaap Net Income Loss
NetIncomeLoss
287000
us-gaap Net Income Loss
NetIncomeLoss
-55426000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
145000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
16000
nwbo Amortization Of Debt Discount
AmortizationOfDebtDiscount
1357000
nwbo Amortization Of Debt Discount
AmortizationOfDebtDiscount
1073000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
35063000
us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-19899000
us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
39118000
nwbo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
-992000
nwbo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
-500000
nwbo Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
218000
nwbo Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
3000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1424000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
2075000
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-2645000
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-226000
nwbo Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
19000
nwbo Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
94000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20040000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13868000
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
1771000
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
1306000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1771000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1306000
nwbo Proceeds From Issuance Of Capital Stock And Warrants
ProceedsFromIssuanceOfCapitalStockAndWarrants
16000
nwbo Proceeds From Issuance Of Capital Stock And Warrants
ProceedsFromIssuanceOfCapitalStockAndWarrants
11567000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4073000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3997000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
12288000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
3557000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
559000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6225000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5583000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9983000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
372000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3758000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5955000
nwbo Stock Issued During Period Value For Warrant And Stock Options Cashless Exercise
StockIssuedDuringPeriodValueForWarrantAndStockOptionsCashlessExercise
6000
nwbo Adjustments To Additional Paid In Capital Reclassification
AdjustmentsToAdditionalPaidInCapitalReclassification
11394000
nwbo Adjustments To Additional Paid In Capital Reclassification
AdjustmentsToAdditionalPaidInCapitalReclassification
2721000
nwbo Adjustment To Additional Paid In Capital Reclassification Of Cashless Warrants Exercised
AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised
1592000
nwbo Reclassification Of Warrant Liabilities Based On Authorized Shares
ReclassificationOfWarrantLiabilitiesBasedOnAuthorizedShares
25548000
nwbo Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest Received
IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived
7487000
nwbo Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest Received
IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived
3558000
nwbo Offering Cost Related To Warrant Liability
OfferingCostRelatedToWarrantLiability
3842000
nwbo Capital Expenditures Included In Accounts Payable
CapitalExpendituresIncludedInAccountsPayable
592000
nwbo Capital Expenditures Included In Accounts Payable
CapitalExpendituresIncludedInAccountsPayable
809000
nwbo Warrants Issued Associated With Convertible Notes Payable To Related Party
WarrantsIssuedAssociatedWithConvertibleNotesPayableToRelatedParty
153000
nwbo Warrant Modification In Connection With Debt Amendment
WarrantModificationInConnectionWithDebtAmendment
51000
us-gaap Net Income Loss
NetIncomeLoss
300000
us-gaap Payments For Operating Activities
PaymentsForOperatingActivities
20000000.0
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In preparing condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include recoverability and useful lives (indefinite) of intangible asset, assessment of impairment of goodwill, valuing equity securities in share-based payment arrangements, estimating the fair value of financial instruments recorded as derivative liabilities, useful lives of depreciable assets and whether impairment charges may apply.</p>
CY2021Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
332803000
CY2021Q2 nwbo Contingent Payable Derivative Liability
ContingentPayableDerivativeLiability
8656000
CY2021Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
341459000
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
354972000
CY2020Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
2507000
CY2020Q4 nwbo Contingent Payable Derivative Liability
ContingentPayableDerivativeLiability
8275000
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
365754000
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
365754000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
131000
nwbo Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification For Warrants Exercised For Cash
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationForWarrantsExercisedForCash
-12562000
nwbo Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements Related To Debt Conversion
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRelatedToDebtConversion
-1925000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-35063000
CY2021Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
341459000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3551000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13369000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
399000
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
308840
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.33
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M24D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
372219000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
910
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.92
nwbo Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm
P9Y1M6D
nwbo Stockissued During Period Shares Stock Options Cash Exercised
StockissuedDuringPeriodSharesStockOptionsCashExercised
183
nwbo Sharebasedcompensationarrangementsbysharebasedpaymentawardoptions Cash Exercises In Period Weighted Average Exercise Price
SharebasedcompensationarrangementsbysharebasedpaymentawardoptionsCashExercisesInPeriodWeightedAverageExercisePrice
0.25
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3788
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.25
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
305779
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.33
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
349032000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
272701
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.32
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y6M
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
313455000
nwbo Share Based Compensation Arrangement By Share Based Payment Award Period Of Notice For Exercising Any Option
ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfNoticeForExercisingAnyOption
P61D
CY2021Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
21276000
CY2021Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1226000
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
20050000
CY2020Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
13751000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1484000
CY2020Q4 nwbo Fair Value Of Embedded Conversion Option
FairValueOfEmbeddedConversionOption
2507000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
14774000
CY2021Q1 nwbo Debt Instrument Original Issue Discount Amount
DebtInstrumentOriginalIssueDiscountAmount
1000000
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
5600000
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
5100000
us-gaap Debt Conversion Converted Instrument Warrants Or Options Issued1
DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
800000
CY2021Q2 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
7500000
us-gaap Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
1900000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
4410000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-58052000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
287000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-55426000
CY2021Q2 nwbo Reversal Of Gain Due To Change In Fair Value Of Warrant Liability
ReversalOfGainDueToChangeInFairValueOfWarrantLiability
-17500000
nwbo Reversal Of Gain Due To Change In Fair Value Of Warrant Liability
ReversalOfGainDueToChangeInFairValueOfWarrantLiability
-35063000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-13090000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-58052000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-34776000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-55426000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
851805
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
697555
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
843252
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
668972
CY2021Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
74000
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
74000
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1159076
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
697555
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1147423
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
668972
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
313717000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
454626000
nwbo Extended Term Of Agreement
ExtendedTermOfAgreement
P12M
nwbo Extended Term Of Agreement
ExtendedTermOfAgreement
P12M
CY2021Q2 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
1800000
CY2020Q2 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
1300000
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
3500000
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
2800000
nwbo Capitalized Cost Amortization
CapitalizedCostAmortization
1400000
nwbo Capitalized Cost Amortization
CapitalizedCostAmortization
800000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4100000
nwbo Stock Issued During Period Shares Warrant Exercises
StockIssuedDuringPeriodSharesWarrantExercises
16200000
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
331753
CY2020Q4 nwbo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.28
CY2020 nwbo Class Of Warrant Or Right Outstanding Remaining Contractual Term
ClassOfWarrantOrRightOutstandingRemainingContractualTerm
P1Y7M9D
nwbo Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
774
nwbo Class Of Warrant Or Right Granted Weighted Average Exercise Price
ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice
2.00
nwbo Number Of Warrants Warrants Exercised For Cash
NumberOfWarrantsWarrantsExercisedForCash
16014
nwbo Weighted Average Exercise Price Exercised For Cash
WeightedAverageExercisePriceExercisedForCash
0.25
nwbo Number Of Warrants Warrants Cashless Exercise
NumberOfWarrantsWarrantsCashlessExercise
3577
nwbo Weighted Average Exercise Price Warrants Cashless Exercise
WeightedAverageExercisePriceWarrantsCashlessExercise
0.24
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
us-gaap Lease Cost
LeaseCost
555000
us-gaap Operating Lease Payments
OperatingLeasePayments
431000
nwbo Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
901
nwbo Class Of Warrant Or Right Expired Weighted Average Exercise Price
ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice
0.0332
CY2021Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
312035
CY2021Q2 nwbo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.28
nwbo Class Of Warrant Or Right Outstanding Remaining Contractual Term
ClassOfWarrantOrRightOutstandingRemainingContractualTerm
P1Y4M17D
CY2021Q2 us-gaap Lease Practical Expedient Lessor Single Lease Component
LeasePracticalExpedientLessorSingleLeaseComponent
true
CY2021Q1 nwbo Lessee Operating Additional Lease Term
LesseeOperatingAdditionalLeaseTerm
P3Y5M
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
5800000
CY2021Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P20Y
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5100000
us-gaap Operating Lease Cost
OperatingLeaseCost
477000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
25000
us-gaap Variable Lease Cost
VariableLeaseCost
53000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
441000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
982000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
991000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
897000
CY2021Q2 nwbo Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
9663000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
12974000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7219000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
5755000
nwbo Original Term Of Agreement
OriginalTermOfAgreement
P8M
nwbo Extended Term Of Agreement
ExtendedTermOfAgreement
P12M
CY2021Q2 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
120000
CY2021Q2 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
143000
CY2021Q3 nwbo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5700000
CY2021Q3 nwbo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5700000
CY2021Q3 nwbo Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
15200000
CY2021Q3 nwbo Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
15200000
CY2021Q3 nwbo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
3300000
CY2021Q3 nwbo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
3300000

Files In Submission

Name View Source Status
0001104659-21-106389-index-headers.html Edgar Link pending
0001104659-21-106389-index.html Edgar Link pending
0001104659-21-106389.txt Edgar Link pending
0001104659-21-106389-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nwbo-20210630.xsd Edgar Link pending
nwbo-20210630x10q.htm Edgar Link pending
nwbo-20210630x10q_htm.xml Edgar Link completed
nwbo-20210630xex31d1.htm Edgar Link pending
nwbo-20210630xex32d1.htm Edgar Link pending
nwbo-20210630_cal.xml Edgar Link unprocessable
nwbo-20210630_def.xml Edgar Link unprocessable
nwbo-20210630_lab.xml Edgar Link unprocessable
nwbo-20210630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending